A well researched theory of aging, that resulted in the 2009 Nobel Prize in Medicine, holds that DNA telomere shortening holds sway, and that all other factors are secondary. Furthermore, experts believe that substances that promote longer telomeres in human cells may lead to rejuvenation of tissues, a reversal of the aging process.

TrifecTA contains four active ingredients: Astralagus Root Extract, Acetyl-L-Carnitine, Alpha Lipoic Acid and Reseveratro.  All ingredients are encapsulated in nanometer sized lipid bubbles called liposomes.

The four ingredients in the new TrifecTA liposomal product are included to attack aging from three directions simultaneously: Telomeres, Mitochondrial Aging and simulating Calorie Restriction induced Gene Expression.  Currently a pilot study is being run by Immortal founder Owen Fonorow to determine whether this product lengthens short telomeres.

The new liposomal product contains the same astralagus root extract, Cycloastragenol, as other telomerase activation products, this isolate has been sold in pill form for more than 10 years for telomere maintenance. It is designated GRAS by the U.S. Government/FDA (Generally Recognized As Safe).

Research into mitochondrial aging by the Bruse Ames group (UC) made national news when they were able to transform old rats into young rats by restoring mitochondrial function with two nutrients.  These nutrients are the Acetyl-L-Carnitine (ALC) and Alpha Lipoic Acid (ALA).  To our knowledge, our pilot study will be the first to measure telomeres in humans from supplementing these substances. Telomeres were not measured by Ames or mentioned by other groups in these repeatable animal experiments.

Resveratrol is the fourth active ingredient because this extract has been shown to make humans express the same set of anti-aging genes in humans as calorie restricton.  (Note: both Acetyl-L-Carnitine and Alpha Lipoic Acid have also been shown to induce the gene expression for so-called anti-aging genes).

Preorders only.   In clinical trial and coming soon...